Welcome to VIB

Aurelie Nowack– Business Development

5 universities

1508 researchers

66 nationalities

8 research centers

75 research groups

10 core facilities

VIB – it all starts with high quality research

VIB history

• Established in 1996

• Aim was to strengthen the excellence of Flemish life sciences research on the one hand and to turn the results into new economic growth on the other

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

VIB Centers

Translational Neuroscience

Cancer Biology

Microbiology Structural Biology

Inflammation

Plant Systems Biology

Medical Biotechnology

Neurobiology

8 focused research areas

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

VIB’s mission

Curiosity-driven research integrated with value-added tech transfer

TACKLE DISEASE FEED GROWING WORLD

POPULATION

Healthy living Sustainable food production

Results and impact

• > 840 peer reviewed publications / year

• > 250 breakthrough articles

• 75 PhD /year

34 ERC grants + 5 POC

VIB research budget ~120M € p.a.

Fellowships

VIB-grant

University Grant funding

International/

Industrial

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

In an innovative environment VIB invests in people, infrastructure and innovation

National & international recruitment

Scientific independence

Open dialogue to knowledge sharing

Career development

Training

Well-being

State-of-the-art facilities

Embedded in universities

5 locations in Belgium

Continuous investment in equipment

High-end tech services

Tech watch

Discovery sciences

Core facilities

VIB Bioimaging Core

VIB Bioinformatics Core

VIB Nucleomics Core

VIB Nanobody Core

VIB Proteomics Core

VIB Genomics Core

VIB NMR Core

Core for Life

VIB Metabolomics Core

VIB Screening Core

VIB Protein Core

State-of-the-art core facilities

R:233 G:98 B:64

R:89 G:46 B:133

R:16 G:157 B:153

R:124 G:124 B:124

Facilities and infrastructure at PSB

Bio-imaging core facility, including super resolution microscope

Compound screening facility

Applied Bioformatics and Biostatistics

Transformation service and Crop genome engineering facility

Large greenhouses, > 20 walk-in growth chambers, 6 large tissue culture rooms

Top-notch infrastructure for metabolomics & proteomics

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

Our research groups 20 group leaders

Dirk INZÉ

Director

Geert DE JAEGER

Vice Director

Tom BEECKMAN

Wout BOERJAN

Ann DEPICKER

Ive DE SMET

Lieven DE VEYLDER

Alain GOOSSENS

Steven MAERE

Moritz NOWACK

Jenny RUSSINOVA

Frank VAN BREUSEGEM

Daniël VAN DAMME

Yves VAN DE PEER

Mieke VAN LIJSEBETTENS

Bruno CAMMUE

Thomas JACOBS

Sofie GOORMACHTIG

Bert DE RYBEL

9 of the 32 Belgian ISI highly-cited researchers (all disciplines) are from PSB

Klaas VANDEPOELE

R:233 G:98 B:64

R:89 G:46 B:133

R:16 G:157 B:153

R:124 G:124 B:124

Grand Challenges

Sustainable bio-energy & bio-resources

Climate resilient crops Innovative crop care

Plant diversity Plants and human health

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

Science communication

• Information and tools tailored to specific audiences

• Events, dossiers, regulatory affairs

Conference series

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

Biotechnology Outreach – the mission of IPBO

Develop projects allowing transfer of knowledge, tools and technologies to developing countries for a sustainable development

of agriculture and agro-industry.

Networking

Communication Capacity building

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

• 571 patent applications

• 283 patents granted

> 1200 partnerships with industry

> M€ 300 industrial revenue

• 20 spin-offs and inward investments : >1200 jobs

• VIB spin-offs attracted M€ 1,165 capital investment (>50% foreign)

Creating opportunities through tech transfer

VIB’s instruments to increase value

• Flexible financial instrument • Endorsement of VIB’s

commitment

• From innovative targets towards novel pharmacology

• Industry-trained discovery team

• Early stage venture fund • Increase output of novel

innovative ventures

• Validation of IP • In-licensing assets • Combination of IP/assets

VIB approach towards start-ups

VIB start-ups: a magnet for foreign investors

823 employees

€ 1,2B€ total investment

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

Role of VIB in the biotech cluster Creating value for society